Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development

被引:18
作者
Cheng, Yaofeng [1 ]
El-Kattan, Ayman [2 ]
Zhang, Yan [3 ]
Ray, Adrian S. [4 ]
Lai, Yurong [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Candidate Optimizat, 3551 Lawrenceville Rd, Princeton, NJ 08540 USA
[2] Pfizer Inc, Dept Pharmacokinet Dynam & Metab, 610 Main St, Cambridge, MA 02139 USA
[3] Incyte Corp, Drug Metab & Biopharmaceut, 1801 Augustine Cutoff, Wilmington, DE 19803 USA
[4] Gilead Sci Inc, Dept Drug Metab, 353 Lakeside Dr, Foster City, CA 94404 USA
关键词
SALT EXPORT PUMP; FAMILIAL INTRAHEPATIC CHOLESTASIS; BILE-ACID MALABSORPTION; ANION TRANSPORTER; SEROTONIN TRANSPORTER; TOXIN EXTRUSION; P-GLYCOPROTEIN; LIVER-DISEASE; IN-VITRO; TARGETED INACTIVATION;
D O I
10.1021/acs.chemrestox.5b00511
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Membrane transporters play a pivotal role in many organs to maintain their normal physiological functions and contribute significantly to drug absorption, distribution, and elimination. Knowledge gained from gene modified animal models or human genetic disorders has demonstrated that interruption of the transporter activity can lead to debilitating diseases or organ toxicities. Herein we describe transporter associated diseases and organ toxicities resulting from transporter gene deficiency or functional inhibition in the liver, kidney, gastrointestinal tract (GIT), and central nervous system (CNS). While proposing additional transporters as targets for drug-induced organ toxicity, strategies and future perspectives are discussed for transporter risk assessment in drug discovery and development.
引用
收藏
页码:545 / 563
页数:19
相关论文
共 158 条
  • [1] Agladioglu SY, 2012, GENET COUNSEL, V23, P149
  • [2] New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Ali, Rafeeq
    Cusi, Kenneth
    [J]. ANNALS OF MEDICINE, 2009, 41 (04) : 265 - 278
  • [3] [Anonymous], 2013, FDA GUID PRECL ASS
  • [4] Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors
    Aronica, E
    Gorter, JA
    Jansen, GH
    Van Veelen, CWM
    Van Rijen, PC
    Leenstra, S
    Ramkema, M
    Scheffer, GL
    Scheper, RJ
    Troost, D
    [J]. NEUROSCIENCE, 2003, 118 (02) : 417 - 429
  • [5] Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy
    Bakhiya, Nadiya
    Arlt, Volker M.
    Bahn, Andrew
    Burckhardt, Gerhard
    Phillips, David H.
    Glatt, Hansruedi
    [J]. TOXICOLOGY, 2009, 264 (1-2) : 74 - 79
  • [6] Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases
    Barnes, Sarah N.
    Aleksunes, Lauren M.
    Augustine, Lisa
    Scheffer, George L.
    Goedken, Michael J.
    Jakowski, Amy B.
    Pruimboom-Brees, Ingrid M.
    Cherrington, Nathan J.
    Manautou, Jose E.
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) : 1963 - 1969
  • [7] Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis
    Beasley, CM
    Koke, SC
    Nilsson, ME
    Gonzales, JS
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (11) : 1319 - +
  • [8] Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities
    Beck, L
    Karaplis, AC
    Amizuka, N
    Hewson, AS
    Ozawa, H
    Tenenhouse, HS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) : 5372 - 5377
  • [9] Regulation of γ-aminobutyric acid (GABA) transporters by extracellular GABA
    Bernstein, EM
    Quick, MW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) : 889 - 895
  • [10] Microfluidic organs-on-chips
    Bhatia, Sangeeta N.
    Ingber, Donald E.
    [J]. NATURE BIOTECHNOLOGY, 2014, 32 (08) : 760 - 772